Etudes et Recherche en Economie de la Santé

Publications Etudes et Recherche en Economie de la Santé 2023-24

• 1.    Lueza B, Aupérin A, Rigaud C, Gross TG, Pillon M, Delgado RF, Uyttebroeck A, Amos Burke GA, Zsíros J, Csóka M, Simonin M, Patte C, Minard-Colin V, Bonastre J. Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin's lymphoma. Eur J Health Econ. 2024 Mar;25(2):307-317.
• 2.    Rousseau A, Michiels S, Simon-Tillaux N, Lolivier A, Bonastre J, Planchard D, Barlesi F, Remon J, Lavaud P, Aldea M, Frelaut M, Le Pechoux C, Botticella A, Levy A, Gazzah A, Foulon S, Besse B. Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study. Lancet Reg Health Eur. 2024 Jun 29;43:100970.
• 3.    Mosele MF, Westphalen CB, Stenzinger A, Barlesi F, Bayle A, Bièche I, Bonastre J, Castro E, Dienstmann R, Krämer A, Czarnecka AM, Meric-Bernstam F, Michiels S, Miller R, Normanno N, Reis-Filho J, Remon J, Robson M, Rouleau E, Scarpa A, Serrano C, Mateo J, André F. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2024 Jul;35(7):588-606.
• 4.    Bayle A, Chaltiel D, Latino N, Rouleau E, Peters S, Galotti M, Bricalli G, Besse B, Giuliani R, Bonastre J. Reply to the Letter to the Editor regarding 'Overcoming Barriers in Biomarker Testing' J. García-Foncillas et al. Ann Oncol. 2024 Sep;35(9):829-830.
• 5.    Bayle A, Marino P, Baffert S, Margier J, Bonastre J. Coût des technologies de séquençage haut débit (NGS) : revue de la littérature et enseignements [Cost of high-throughput sequencing (NGS) technologies: Literature review and insights]. Bull Cancer. 2024 Feb;111(2):190-198. French.
• 6.    Farah L, Borget I, Martelli N, Vallee A. Suitability of the Current Health Technology Assessment of Innovative Artificial Intelligence-Based Medical Devices: Scoping Literature Review. J Med Internet Res. 2024 May 13;26:e51514.
• 7.    Gourdy P, Darmon P, Borget I, Emery C, Bureau I, Detournay B, Bahloul A, Allali N, Mahieu A, Penfornis A. Basal Insulinotherapy in Patients Living with Diabetes in France: The EF-BI Study. Diabetes Ther. 2024 Jun;15(6):1349-1360. Epub 2024 Apr 20. Erratum in: Diabetes Ther. 2024 Sep;15(9):2131-2132.
• 8.    Martin T, Rioufol C, Favier B, Martelli N, Madelaine I, Chouaid C, Borget I. Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs. BioDrugs. 2024 May;38(3):465-475.
• 9.    Borget I, Benchaib M, Poignant P, Rey L, Harty G, Chaudhari V, D'hooghe T, Schwarze JE, Cedrin Durnerin I, Roeder C, Grynberg M. A Cost-Effectiveness Analysis of Gonadotropins Used for Ovarian Stimulation during Assisted Reproductive Technology Based on Data from the French Nationwide Claims Database (SNDS). Gynecol Obstet Invest. 2024 Nov 19:1-15. Grumberg V, Cotté FE, Giroux-Leprieur E, Gaudin AF, Lebbé C, Borget I. Clinical benefit of anti-PD-(L)1 immunotherapies in advanced cancer in France: a population-based estimate from 2014 to 2021. ESMO Open. 2024 Feb;9(2):102240.
• 10.    Cartron G, Thieblemont C, Borget I, Rioufol C, Berthet M, Portal C, Baujat C, Alaoui E, Baffert S, Lacroix D, Bories P, Yakoub-Agha I, Houot R. Évaluation en vie réelle du parcours de soins des patients éligibles à un traitement par axicabtagene ciloleucel : cohorte multicentrique IMPA-CT [Real-life evaluation of the care pathway of patients eligible for axicabtagene ciloleucel treatment: Analysis of a multicenter retrospective cohort (IMPA-CT study)]. Bull Cancer. 2024 Nov;111(11):1020-1029. French.
• 11.    Horgan D, Pesapane F, Van der Buckle M, de Maria R, Dube F, Singh J, Ługowska I, Bayle A, Hofman P, Malapelle U, Hills T, Capoluongo ED, Subbiah V. From theory to practice: Implementing next-generation sequencing and public health genomics in healthcare systems. Crit Rev Oncol Hematol. 2024 Sep;201:104433.
• 12.    Lebret T, Bonastre J, Fraslin A, Neuzillet Y, Droupy S, Rebillard X, Vordos D, Guy L, Villers A, Schneider M, Coloby P, Lacoste J, Méjean A, Lacoste J, Descotes JL, Eschwege P, Loison G, Blanché H, Mariani O, Ghaleh B, Mangin A, Sirab N, Groussard K, Radvanyi F, Allory Y, Benhamou S. Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life. BMJ Open. 2023 Dec 20;13(12):e075942.
• 13.    Bergerot CD, Bonastre J. Health-related Quality of Life and Cost Effectiveness of Treatment: Components to Be Included in Clinical Decision-making. Eur Urol Oncol. 2023 Jun;6(3):349-350.
• 14.    Bayle A, Bonastre J, Chaltiel D, Latino N, Rouleau E, Peters S, Galotti M, Bricalli G, Besse B, Giuliani R. ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe. Ann Oncol. 2023 Oct;34(10):934-945.
• 15.    Le Corroller AG, Bonastre J. Patient-reported measures: how useful in health economics? Eur J Health Econ. 2023 Feb;24(1):1-4.
• 16.    Palmer S, Borget I, Friede T, Husereau D, Karnon J, Kearns B, Medin E, Peterse EFP, Klijn SL, Verburg-Baltussen EJM, Fenwick E, Borrill J. A Guide to Selecting Flexible Survival Models to Inform Economic Evaluations of Cancer Immunotherapies. Value Health. 2023 Feb;26(2):185-192.
• 17.    de Pouvourville G, Armoiry X, Lavorel A, Bilbault P, Maugendre P, Bensimon L, Beziz D, Blin P, Borget I, Bouée S, Collignon C, Dervaux B, Durand-Zaleski I, Julien M, de Léotoing L, Majed L, Martelli N, Séjourné T, Viprey M. Données et preuves en vie réelle dans l’évaluation des technologies de santé : dans quels cas sont-elles complémentaires, substitutives, ou les seules sources de données par rapport aux essais cliniques ? Therapie. 2023 Jan-Feb;78(1):66-80.
• 18.    Roze S, Bertrand N, Eberst L, Borget I. Projecting overall survival in health-economic models: uncertainty and maturity of data. Curr Med Res Opin. 2023 Mar;39(3):367-374.
• 19.    Grumberg V, Chouaïd C, Gaudin AF, Le Tourneau C, Marabelle A, Bongiovanni-Delarozière I, Cotté FE, Borget I. Organizational Impact of Immunotherapies in Advanced Cancers in France. JCO Glob Oncol. 2023 Aug;9:e2300026.
• 20.    Martin T, Guercio A, Besseau H, Huot L, Guerre P, Atfeh J, Piazza L, Pineau J, Sabatier B, Borget I, Martelli N. Hospital-based health technology assessment of innovative medical devices: insights from a nationwide survey in France. Int J Technol Assess Health Care. 2023 Sep 21;39(1):e58.
• 21.    Farah L, Davaze-Schneider J, Martin T, Nguyen P, Borget I, Martelli N. Are current clinical studies on artificial intelligence-based medical devices comprehensive enough to support a full health technology assessment? A systematic review. Artif Intell Med. 2023 Jun;140:102547.
• 22.    Jenei K, Raymakers AJN, Bayle A, Berger-Thürmel K, Cherla A, Honda K, Jackson CCGA, Karikios D, Trapani D, Berry S, Gyawali B. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study. Lancet Oncol. 2023 Jun;24(6):624-635. doi: 10.1016/S1470-2045(23)00175-4. PMID: 37269843.

Publications Etudes et Recherche en Economie de la Santé 2014-22

► Liste des publications Etudes et Recherche en Economie de la Santé 2014-2022 (document PDF)